Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Myelofibrosis: early-phase trial registry
15 of 31 indexed Primary Myelofibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 15 currently recruiting · #495 of 28,707 conditions by registered trial count
Primary Myelofibrosis: 31 US clinical trials tracked, 15 recruiting.
Primary Myelofibrosis is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition primary-myelofibrosis
OPEN 15 | RECR 48% | LATE 6 | EARLY 25 | RANK #495 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Genetic Disease (48% recruiting · 31 trials)
Primary Myelofibrosis lists 15 open slots (48% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Myelofibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Myelofibrosis is recruiting above its size-band peers.
15 of 31 indexed trials (48.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Myelofibrosis research.
M.D. Anderson Cancer Center accounts for 5 of 31 trials (16.1%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Primary Myelofibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 31 trials that report a genuine target (sentinel values excluded). 23 of those (74.2%) plan for fewer than 100 participants.
-
Primary Myelofibrosis research is mostly interventional.
31 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Kartos Therapeutics
NCT06479135
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme
NCT06351631
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum
NCT03165734
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine
NCT05320198
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Ajax Therapeutics
NCT06343805
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Telios Pharma
NCT05280509
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
NCT06661915
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
GlaxoSmithKline
NCT06517875
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
NCT07228624
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
M.D. Anderson Cancer Center
NCT06327100
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04282187
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
NCT06218628
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT04370301
Study of Canakinumab in Patients With Myelofibrosis
John Mascarenhas
NCT05467800
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Novartis Pharmaceuticals
NCT04603495
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Celgene
NCT04717414
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT01787487
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT02251821
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
City of Hope Medical Center
NCT04339101
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT04384692
Decitabine in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
NCT00095784
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT05364762
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
M.D. Anderson Cancer Center
NCT04517851
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Celgene
NCT01178281
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Geron Corporation
NCT01731951
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma
NCT01423851
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
NCT00047190
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
NCT01428635
MPN-RC 118 AVID200 in Myelofibrosis
John Mascarenhas
NCT03895112
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
M.D. Anderson Cancer Center
NCT03426969
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 16 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Myelofibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Myelofibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Myelofibrosis page
31 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Primary Myelofibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Primary Myelofibrosis trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Myelofibrosis condition card totals 31 registered trials; most-linked intervention Ruxolitinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.